NPM’s NanoPortal technology has potential applications in a broad range of small molecules, peptides, and even monoclonal antibodies. To prove the technology, Nano Precision Medical has focused on delivering a GLP-1 receptor agonist for metabolic diseases such as type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). NPM intends to use the technology to develop a portfolio of products in other therapeutic areas, including, for example, oncology, infectious disease, and neurology.
High GLP-1 levels increases satiety through delayed gastric emptying.
GLP-1 agonists enhance insulin sensitivity and insulin secretion.
Exenatide was first approved for treating type 2 diabetes in 2005.